Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Next Previous
Trial Profile

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisaftoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ascentage Pharma

Most Recent Events

  • 10 Jul 2025 According to Ascentage Pharma media release, based on results form APG2575CC201 trial the China's National Medical Products Administration (NMPA) has approved lisaftoclax (APG-2575) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton's tyrosine kinase (BTK) inhibitors.
  • 17 Nov 2024 According to Ascentage Pharma media release, company announced that a New Drug Application for lisaftoclax, for the treatment of patients with relapsed or refractory (r/r) CLL/SLL has been accepted and recommended the Priority Review designation by the Center for Drug Evaluation) of China National Medical Products Administration. This NDA is based on results from this pivotal registrational Phase II study in China (APG2575CC201).
  • 22 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top